Selection bias in clinical trials
- PMID: 4020412
- DOI: 10.1200/JCO.1985.3.8.1142
Selection bias in clinical trials
Abstract
Of 90 patients with intermediate or high-grade sarcoma eligible for a randomized trial of adjuvant doxorubicin (Adriamycin, Adria Laboratories, Columbus, Ohio), 48 were not entered: 24 (27%) by physician's choice and 24 refused randomization. Sixty-five percent of lower stage patients were randomized compared with 37% of those with higher stage (P = .02). Patients with extremity lesions were more frequently offered participation in the study (P = .07). Patients with lower stage lesions accepted randomization more readily than those with higher stage lesions (P = .01). As predicted by the higher stage and percentage of central lesions, the disease-free survival of nonrandomized patients was inferior to that of randomized patients (P = .15). Thus, patients at high risk appeared to avoid randomization and adjuvant doxorubicin in this trial, resulting in an inferior disease-free survival for the nonrandomized control group. Important questions generally require randomized trials that reliably determine relative treatment differences. If, however, the patients in a clinical trial are not representative of the entire patient population because of patient and physician selection biases, the generalizability of the results to the entire patient population may be compromised. For example, the prognosis of the general population cannot necessarily be inferred from the selected group in the study. In this study, the randomized and nonrandomized series yielded differing conclusions regarding treatment efficacy, even when an adjustment was made for known prognostic facts.
Similar articles
-
Eastern Cooperative Oncology Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma.J Clin Oncol. 1987 Apr;5(4):613-7. doi: 10.1200/JCO.1987.5.4.613. J Clin Oncol. 1987. PMID: 3549990 Clinical Trial.
-
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.J Clin Oncol. 1985 Sep;3(9):1240-5. doi: 10.1200/JCO.1985.3.9.1240. J Clin Oncol. 1985. PMID: 3897471 Clinical Trial.
-
Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.J Clin Oncol. 1984 Jun;2(6):601-8. doi: 10.1200/JCO.1984.2.6.601. J Clin Oncol. 1984. PMID: 6374055 Clinical Trial.
-
Clinical trials.Semin Surg Oncol. 1996 Jan-Feb;12(1):32-8. doi: 10.1002/(SICI)1098-2388(199601/02)12:1<32::AID-SSU5>3.0.CO;2-7. Semin Surg Oncol. 1996. PMID: 8821407 Review.
-
Adjuvant chemotherapy of adult patients with soft tissue sarcomas.Important Adv Oncol. 1985:273-94. Important Adv Oncol. 1985. PMID: 3916745 Review.
Cited by
-
Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994.Br J Cancer. 2001 Sep 14;85(6):808-15. doi: 10.1054/bjoc.2001.1955. Br J Cancer. 2001. PMID: 11556829 Free PMC article.
-
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.Br J Cancer. 2002 Aug 27;87(5):562-6. doi: 10.1038/sj.bjc.6600433. Br J Cancer. 2002. PMID: 12189557 Free PMC article.
-
Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study.Br J Cancer. 2014 Jan 7;110(1):230-41. doi: 10.1038/bjc.2013.650. Epub 2013 Oct 22. Br J Cancer. 2014. PMID: 24149174 Free PMC article.
-
Does random treatment assignment cause harm to research participants?PLoS Med. 2006 Jun;3(6):e188. doi: 10.1371/journal.pmed.0030188. PLoS Med. 2006. PMID: 16719548 Free PMC article.
-
Clinical trial participants compared with nonparticipants in cystic fibrosis.Am J Respir Crit Care Med. 2006 Jan 1;173(1):98-104. doi: 10.1164/rccm.200502-273OC. Epub 2005 Sep 28. Am J Respir Crit Care Med. 2006. PMID: 16192455 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials